TY - JOUR
T1 - Management of diabetic retinopathy
T2 - could lipid-lowering be a worthwhile treatment modality
AU - Dodson, P.M.
PY - 2009/5
Y1 - 2009/5
N2 - Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.
AB - Diabetic eye disease confers substantial burden on the patient quality of life. Current therapeutic strategies indicate an unmet clinical need for preventive therapy. Tight control of blood pressure and glycaemia are mandatory components of primary prevention strategies, but are insufficient to eliminate risk in all patients. A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Although inconclusive for statin therapy, results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy. However, there is a need for confirmation of these findings in large prospective studies with progression of retinopathy as the primary endpoint, such as the ACCORD-EYE (Action to Control Cardiovascular Risk in Diabetes-EYE) study, and in a clinical trial specifically conducted for diabetic maculopathy. In addition, elucidation of the mechanism(s) of effect of fenofibrate is indicated.
KW - diabetic retinopathy
KW - fenofibrate
KW - FIELD
KW - lipid-lowering
KW - macular oedema
KW - treatment
UR - https://www.nature.com/eye/journal/v23/n5/full/eye2008428a.html
UR - http://www.scopus.com/inward/record.url?scp=65949123780&partnerID=8YFLogxK
U2 - 10.1038/eye.2008.428
DO - 10.1038/eye.2008.428
M3 - Review article
C2 - 19169236
AN - SCOPUS:65949123780
SN - 0950-222X
VL - 23
SP - 997
EP - 1003
JO - Eye
JF - Eye
IS - 5
ER -